Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 17

1.

Identification of CYP2C19*4B: pharmacogenetic implications for drug metabolism including clopidogrel responsiveness.

Scott SA, Martis S, Peter I, Kasai Y, Kornreich R, Desnick RJ.

Pharmacogenomics J. 2012 Aug;12(4):297-305. doi: 10.1038/tpj.2011.5. Epub 2011 Mar 1.

PMID:
21358751
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Genetic causes of clopidogrel nonresponsiveness: which ones really count?

Momary KM, Dorsch MP, Bates ER.

Pharmacotherapy. 2010 Mar;30(3):265-74. doi: 10.1592/phco.30.3.265. Review.

PMID:
20180610
[PubMed - indexed for MEDLINE]
3.

CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis.

Holmes MV, Perel P, Shah T, Hingorani AD, Casas JP.

JAMA. 2011 Dec 28;306(24):2704-14. doi: 10.1001/jama.2011.1880. Review.

PMID:
22203539
[PubMed - indexed for MEDLINE]
4.

Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations.

Ellis KJ, Stouffer GA, McLeod HL, Lee CR.

Pharmacogenomics. 2009 Nov;10(11):1799-817. doi: 10.2217/pgs.09.143. Review.

PMID:
19891556
[PubMed - indexed for MEDLINE]
5.

Pharmacogenomics of clopidogrel: evidence and perspectives.

Yin T, Miyata T.

Thromb Res. 2011 Oct;128(4):307-16. doi: 10.1016/j.thromres.2011.04.010. Epub 2011 May 18. Review.

PMID:
21592545
[PubMed - indexed for MEDLINE]
6.

Genetic determinants of platelet response to clopidogrel.

Kubica A, Kozinski M, Grzesk G, Fabiszak T, Navarese EP, Goch A.

J Thromb Thrombolysis. 2011 Nov;32(4):459-66. doi: 10.1007/s11239-011-0611-8. Review.

PMID:
21706290
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

[Genetic variability in the efficacy of clopidogrel].

Kristensen KE, Rasmussen HB, Hansen PR.

Ugeskr Laeger. 2013 Mar 11;175(11):729-32. Review. Danish.

PMID:
23480885
[PubMed - indexed for MEDLINE]
8.

Cytochrome P450 2C19 polymorphism and antiplatelet therapy. Who should really be genotyped?

Kassimis G, Stavrou EF, Alexopoulos D, Athanassiadou A.

Curr Pharm Des. 2013;19(13):2489-95. Review.

PMID:
23360266
[PubMed - indexed for MEDLINE]
9.

Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel.

Zabalza M, Subirana I, Sala J, Lluis-Ganella C, Lucas G, Tomás M, Masiá R, Marrugat J, Brugada R, Elosua R.

Heart. 2012 Jan;98(2):100-8. doi: 10.1136/hrt.2011.227652. Epub 2011 Jun 21. Review.

PMID:
21693476
[PubMed - indexed for MEDLINE]
10.

Clopidogrel pharmacogenetics: metabolism and drug interactions.

Close SL.

Drug Metabol Drug Interact. 2011;26(2):45-51. doi: 10.1515/DMDI.2011.002. Review.

PMID:
21819266
[PubMed - indexed for MEDLINE]
11.

Applications of CYP450 testing in the clinical setting.

Samer CF, Lorenzini KI, Rollason V, Daali Y, Desmeules JA.

Mol Diagn Ther. 2013 Jun;17(3):165-84. doi: 10.1007/s40291-013-0028-5. Review.

PMID:
23588782
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis.

Bauer T, Bouman HJ, van Werkum JW, Ford NF, ten Berg JM, Taubert D.

BMJ. 2011 Aug 4;343:d4588. doi: 10.1136/bmj.d4588. Review.

PMID:
21816733
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

The influence of CYP2C19 polymorphisms on the pharmacokinetics, pharmacodynamics, and clinical effectiveness of P2Y(12) inhibitors.

Price MJ, Tantry US, Gurbel PA.

Rev Cardiovasc Med. 2011;12(1):1-12. doi: 10.3909/ricm0590. Review.

PMID:
21546883
[PubMed - indexed for MEDLINE]
14.

Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17.

Li-Wan-Po A, Girard T, Farndon P, Cooley C, Lithgow J.

Br J Clin Pharmacol. 2010 Mar;69(3):222-30. doi: 10.1111/j.1365-2125.2009.03578.x. Review.

PMID:
20233192
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy.

Scott SA, Sangkuhl K, Gardner EE, Stein CM, Hulot JS, Johnson JA, Roden DM, Klein TE, Shuldiner AR; Clinical Pharmacogenetics Implementation Consortium.

Clin Pharmacol Ther. 2011 Aug;90(2):328-32. doi: 10.1038/clpt.2011.132. Epub 2011 Jun 29. Review. No abstract available.

PMID:
21716271
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

The gain-of-function variant allele CYP2C19*17: a double-edged sword between thrombosis and bleeding in clopidogrel-treated patients.

Li Y, Tang HL, Hu YF, Xie HG.

J Thromb Haemost. 2012 Feb;10(2):199-206. doi: 10.1111/j.1538-7836.2011.04570.x. Review.

PMID:
22123356
[PubMed - indexed for MEDLINE]
17.

Progress of antiplatelet pharmacogenomics.

Oestreich JH.

Curr Drug Targets. 2011 Nov;12(12):1848-58. Review.

PMID:
21718233
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk